Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
AGMB Stock — AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV American Depositary Shares (AGMB)
Updated November 13, 2026.
AGMB is a stock. Total return is -60.2% over the past 0.8 years, 72.4 points behind SPY at 12.2%.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company developing disease-modifying therapies for immunology and inflammatory diseases, with a pipeline including oral and inhaled small molecule inhibitors for conditions such as Fibrostenosing Crohn's disease and idiopathic pulmonary fibrosis, as well as a monoclonal antibody candidate. The company does not currently distribute to shareholders. This security appeals to investors with a high risk tolerance seeking exposure to early-stage drug development, as the company remains in clinical trials with no approved products generating revenue.
AGMB performance versus SPY
Total return is -60.2% over the past 0.8 years, 72.4 points behind SPY at 12.2%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -27.8% | — |
| 3M | -54.4% | — |
| 6M | -43.1% | — |
| YTD | -60.2% | — |
| Since inception 2026-02-05 · 0.8 years | -60.2% | — |
AGMB key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 02/05/2026
- Distribution frequency
- None
- Last close
- $6.36 (as of 2026-11-13)
- Market cap
- $313,217,121
- Average volume
- 192,639
- Payout ratio
- 0.0%
- EPS
- -$2.08
How Dividend Vision calculates returns
Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
AGMB risks and drawbacks
Total return has trailed SPY over the available window.
Who may consider AGMB — and who may not
It is a weaker fit for investors who need monthly cash flow (AGMB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on AGMB
Frequently asked questions
Does AGMB pay monthly?
No. AGMB does not currently distribute.
When does AGMB pay a dividend?
AGMB does not currently distribute.
How has AGMB performed?
Total return is -60.2% over the past 0.8 years, 72.4 points behind SPY at 12.2%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.